Whitney S Rice1, Kaylee B Crockett, Michael J Mugavero, James L Raper, Ghislaine C Atkins, Bulent Turan. 1. *Department of Psychology, College of Arts and Sciences, University of Alabama at Birmingham, Birmingham, AL; †Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, AL; and ‡School of Nursing, University of Alabama at Birmingham, Birmingham, AL.
Abstract
BACKGROUND: Internalized HIV-related stigma acts as a barrier to antiretroviral therapy (ART) adherence, but its effects on other HIV care continuum outcomes are unclear. METHODS: Among 196 HIV clinic patients in Birmingham, AL, we assessed internalized HIV-related stigma and depressive symptom severity using validated multi-item scales and assessed ART adherence using a validated single-item measure. HIV visit adherence (attended out of total scheduled visits) was calculated using data from clinic records. Using covariate-adjusted regression analysis, we investigated the association between internalized stigma and visit adherence. Using path analytic methods with bootstrapping, we tested the mediating role of depressive symptoms in the association between internalized stigma and visit adherence and the mediating role of visit adherence in the association between internalized stigma and ART adherence. RESULTS: Higher internalized stigma was associated with lower visit adherence (B = -0.04, P = 0.04). Black (versus white) race and depressive symptoms were other significant predictors within this model. Mediation analysis yielded no indirect effect through depression in the association between internalized stigma and visit adherence (B = -0.18, SE = 0.11, 95% confidence interval: -0.44 to -0.02) in the whole sample. Supplemental mediated moderation analyses revealed gender-specific effects. Additionally, the effect of internalized stigma on suboptimal ART adherence was mediated by lower visit adherence (B = -0.18, SE = 0.11, 95% confidence interval: -0.44 to -0.02). CONCLUSIONS: Results highlight the importance of internalized HIV stigma to multiple and sequential HIV care continuum outcomes. Also, findings suggest multiple intervention targets, including addressing internalized stigma directly, reducing depressive symptoms, and promoting consistent engagement in care.
BACKGROUND: Internalized HIV-related stigma acts as a barrier to antiretroviral therapy (ART) adherence, but its effects on other HIV care continuum outcomes are unclear. METHODS: Among 196 HIV clinic patients in Birmingham, AL, we assessed internalized HIV-related stigma and depressive symptom severity using validated multi-item scales and assessed ART adherence using a validated single-item measure. HIV visit adherence (attended out of total scheduled visits) was calculated using data from clinic records. Using covariate-adjusted regression analysis, we investigated the association between internalized stigma and visit adherence. Using path analytic methods with bootstrapping, we tested the mediating role of depressive symptoms in the association between internalized stigma and visit adherence and the mediating role of visit adherence in the association between internalized stigma and ART adherence. RESULTS: Higher internalized stigma was associated with lower visit adherence (B = -0.04, P = 0.04). Black (versus white) race and depressive symptoms were other significant predictors within this model. Mediation analysis yielded no indirect effect through depression in the association between internalized stigma and visit adherence (B = -0.18, SE = 0.11, 95% confidence interval: -0.44 to -0.02) in the whole sample. Supplemental mediated moderation analyses revealed gender-specific effects. Additionally, the effect of internalized stigma on suboptimal ART adherence was mediated by lower visit adherence (B = -0.18, SE = 0.11, 95% confidence interval: -0.44 to -0.02). CONCLUSIONS: Results highlight the importance of internalized HIV stigma to multiple and sequential HIV care continuum outcomes. Also, findings suggest multiple intervention targets, including addressing internalized stigma directly, reducing depressive symptoms, and promoting consistent engagement in care.
Authors: Anne Zinski; Andrew O Westfall; Lytt I Gardner; Thomas P Giordano; Tracey E Wilson; Mari-Lynn Drainoni; Jeanne C Keruly; Allan E Rodriguez; Faye Malitz; D Scott Batey; Michael J Mugavero Journal: Am J Public Health Date: 2015-08-13 Impact factor: 9.308
Authors: Mallory O Johnson; Torsten B Neilands; Samantha E Dilworth; Stephen F Morin; Robert H Remien; Margaret A Chesney Journal: J Behav Med Date: 2007-06-23
Authors: Sergio Rueda; Sanjana Mitra; Shiyi Chen; David Gogolishvili; Jason Globerman; Lori Chambers; Mike Wilson; Carmen H Logie; Qiyun Shi; Sara Morassaei; Sean B Rourke Journal: BMJ Open Date: 2016-07-13 Impact factor: 2.692
Authors: Whitney S Rice; Bulent Turan; Faith E Fletcher; Tessa M Nápoles; Melonie Walcott; Abigail Batchelder; Mirjam-Colette Kempf; Deborah J Konkle-Parker; Tracey E Wilson; Phyllis C Tien; Gina M Wingood; Torsten B Neilands; Mallory O Johnson; Sheri D Weiser; Janet M Turan Journal: AIDS Patient Care STDS Date: 2019-04 Impact factor: 5.078
Authors: Sannisha K Dale; Taquesha Dean; Ratanpriya Sharma; Rachelle Reid; Sherene Saunders; Steven A Safren Journal: AIDS Patient Care STDS Date: 2019-04 Impact factor: 5.078
Authors: Ann-Margaret Dunn Navarra; Hannah Ford; Charles M Cleland; Eva Liang; Karla Rodriguez; Natalie Neu Journal: J Assoc Nurses AIDS Care Date: 2019 May-Jun Impact factor: 1.354
Authors: Bulent Turan; Whitney S Rice; Kaylee B Crockett; Mallory Johnson; Torsten B Neilands; Shericia N Ross; Mirjam-Colette Kempf; Deborah Konkle-Parker; Gina Wingood; Phyllis C Tien; Mardge Cohen; Tracey E Wilson; Carmen H Logie; Oluwakemi Sosanya; Michael Plankey; Elizabeth Golub; Adaora A Adimora; Carrigan Parish; Sheri D Weiser; Janet M Turan Journal: AIDS Date: 2019-03-01 Impact factor: 4.177